Outset Medical is scheduled to report Q3 2026 results on November 4, with analysts expecting a consensus revenue of $31.40 million and a loss per share of $0.84, while the stock currently trades at $4.03 compared to a $7.67 average price target.
Investors are primarily focused on the growth of recurring revenue from Tablo consumables and services, which is expected to reach approximately $22.8 million for the quarter.
This report follows a transitional 2025 characterized by extended sales cycles and a commercial transformation intended to accelerate console placements among acute-care providers.
Shareholders are also watching for gross margin expansion toward the high-30% range as the company works to reduce cash burn and leverage its installed base of over 1,000 care sites.